$2.25 Billion is the total value of Novo Holdings A/S's 54 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
BAM | Buy | BROOKFIELD ASSET MGMT INCcl a ltd vt sh | $156,768,000 | +14.7% | 3,075,079 | +0.1% | 6.95% | +23.2% |
CYT | New | CYTEIR THERAPEUTICS INC | $103,585,000 | – | 4,840,413 | +100.0% | 4.60% | – |
VERV | New | VERVE THERAPEUTICS INC | $47,794,000 | – | 793,265 | +100.0% | 2.12% | – |
VECT | New | VECTIVBIO HLDG AG | $41,067,000 | – | 3,522,019 | +100.0% | 1.82% | – |
RPHM | New | RENEO PHARMACEUTICALS INC | $32,005,000 | – | 3,430,377 | +100.0% | 1.42% | – |
INSM | Buy | INSMED INC | $19,804,000 | +27.3% | 695,840 | +52.4% | 0.88% | +36.8% |
FOLD | Buy | AMICUS THERAPEUTICS INC | $19,260,000 | -0.7% | 1,997,880 | +1.8% | 0.85% | +6.6% |
IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $17,568,000 | +20.2% | 675,160 | +46.2% | 0.78% | +29.0% |
LEGN | Buy | LEGEND BIOTECH CORPsponsored ads | $11,481,000 | +55.7% | 279,676 | +10.0% | 0.51% | +66.9% |
TMCI | New | TREACE MED CONCEPTS INC | $10,097,000 | – | 323,000 | +100.0% | 0.45% | – |
ABCL | New | ABCELLERA BIOLOGICS INC | $9,292,000 | – | 422,382 | +100.0% | 0.41% | – |
INSP | Buy | INSPIRE MED SYS INC | $8,919,000 | +7.7% | 46,151 | +15.4% | 0.40% | +15.8% |
ZGNX | Buy | ZOGENIX INC | $7,647,000 | -3.7% | 442,550 | +8.8% | 0.34% | +3.4% |
ALNY | New | ALNYLAM PHARMACEUTICALS INC | $5,879,000 | – | 34,679 | +100.0% | 0.26% | – |
PHVS | Buy | PHARVARIS N V | $2,071,000 | +48.0% | 111,144 | +122.3% | 0.09% | +58.6% |
BAMR | New | BROOKFIELD ASSET MGMT REINScl a exch lt vtg | $1,102,000 | – | 21,179 | +100.0% | 0.05% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
VANGUARD INDEX FDS | 41 | Q3 2022 | 64.7% |
INOGEN INC | 34 | Q2 2022 | 68.8% |
VANGUARD INTL EQUITY INDEX F | 29 | Q4 2016 | 37.6% |
AMICUS THERAPEUTICS INC | 22 | Q3 2023 | 4.1% |
AKEBIA THERAPEUTICS INC | 21 | Q3 2020 | 4.8% |
VERONA PHARMA PLC | 21 | Q2 2022 | 1.9% |
CORVUS PHARMACEUTICALS INC | 20 | Q4 2020 | 7.1% |
INSPIRE MED SYS INC | 20 | Q3 2023 | 1.8% |
CABLE ONE INC | 19 | Q3 2023 | 9.7% |
FLEXION THERAPEUTICS INC | 19 | Q3 2021 | 4.7% |
View Novo Holdings A/S's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Cyteir Therapeutics, Inc. | August 03, 2023 | 1,547,136 | 4.4% |
Disc Medicine, Inc. | June 28, 2023 | 1,090,772 | 4.8% |
Galera Therapeutics, Inc. | June 28, 2023 | 2,100,000 | 4.9% |
VectivBio Holding AGSold out | May 26, 2023 | 0 | 0.0% |
LanzaTech Global, Inc. | February 17, 2023 | 15,814,845 | 8.1% |
Bolt Biotherapeutics, Inc.Sold out | January 04, 2023 | 0 | 0.0% |
Arcellx, Inc. | December 12, 2022 | 1,750,000 | 4.0% |
MINERVA SURGICAL INC | November 03, 2022 | 1,322,473 | 4.5% |
Milestone Pharmaceuticals Inc. | October 24, 2022 | 1,378,538 | 4.6% |
Galecto, Inc. | September 30, 2022 | 2,497,791 | 9.8% |
View Novo Holdings A/S's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13D/A | 2024-03-28 |
4 | 2024-03-25 |
SC 13D/A | 2024-03-25 |
4 | 2024-03-20 |
SC 13D/A | 2024-03-20 |
144 | 2024-03-18 |
4 | 2024-03-18 |
SC 13D/A | 2024-03-18 |
144 | 2024-03-14 |
SC 13D/A | 2024-03-07 |
View Novo Holdings A/S's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.